Cadila healthcare launched an anti-obesity drug “Slimona” in India. The drug is used to treat obese patients with associated risk factors like type2 diabetes or dyslipidemia. Slimona (Rimonabant) is a selective CB1 Endocannabinoid (EC) receptor antagonist. The drug comes in a tablet form of strength 20 mg to be consumed before breakfast once a day and is priced at Rs 5.50 a tablet.

Obesity: A person is called obese when his Body Mass Index (BMI) is 30 or above. Obesity is mainly due to uncontrolled diet habits and sedentary lifestyle. In urban India, 29% men and 45% women are overweight. According to WHO statistics, 300 million people are obese all over the world and 1 billion people are overweight. Obesity is the major reason behind increase in incidence of type2 Diabetes.

Slimona is a new class of drug in the treatment of Obesity.

Related posts:

1. Obesity: Statistics, causes and diseases   Obesity and overweight together constitute as one of the top 10 global health problems as per the recent surveys conducted by the World Health Organization (WHO).   Obesity Statistics:...